bluebird bio Announces FDA Approval of ZYNTEGLO®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to bluebird bio Announces FDA Approval of ZYNTEGLO®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions

UPDATE: bluebird bio's (BLUE) Zynteglo Gets FDA Approval - List Price In-Line Says Analyst

August 17, 2022 4:22 PM EDT

(Updated - August 17, 2022 4:23 PM EDT)

bluebird bio's (NASDAQ: BLUE) cell-based gene therapy, Zynteglo, has been approved for the treatment of adult and pediatric patients with beta-thalassemia by the U.S. Food and Drug Administration, it was announced Wednesday.

Beta-thalassemia is a type of inherited blood disorder that causes a reduction of normal hemoglobin and red blood cells in the blood. Zynteglo is the first cell-based gene therapy to treat the blood disorder.

Zynteglo is a one-time gene therapy product administered as a single dose. Its safety and effectiveness were established in... More

bluebird bio (BLUE) Resumes Trading, Up 20%

August 17, 2022 2:30 PM EDT

bluebird bio (NASDAQ: BLUE) Resumes Trading, Up 20%

... More

bluebird bio (BLUE) to Resume Trading at 2:30 p.m.

August 17, 2022 2:10 PM EDT

bluebird bio (NASDAQ: BLUE) to Resume Trading at 2:30 p.m.

... More